A prospect for pharmacogenomics in the interferon therapy of chronic viral hepatitis
Journal
Journal of Antimicrobial Chemotherapy
Journal Volume
52
Journal Issue
2
Pages
149-151
Date Issued
2003
Author(s)
Subjects
Antivirals; Genetic polymorphism; Hepatitis virus
SDGs
Other Subjects
adefovir dipivoxil; adenosine deaminase; alanine aminotransferase; alpha interferon; antivirus agent; gamma interferon; guanosine triphosphatase; initiation factor 2; interferon; interleukin 10; Janus kinase; lamivudine; major histocompatibility antigen class 1; major histocompatibility antigen class 2; mannose binding protein; nitric oxide synthase; nuclease; nucleoside analog; nucleotide derivative; ribavirin; ribonuclease; STAT protein; tumor necrosis factor alpha; virus DNA; virus RNA; antiviral activity; apoptosis; article; cellular immunity; chronic hepatitis; disease course; drug sensitivity; genetic polymorphism; genetic variability; genotype; haplotype; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; host resistance; human; immune response; immunotherapy; liver cell carcinoma; liver cirrhosis; nonhuman; pharmacogenomics; promoter region; single nucleotide polymorphism; treatment outcome; treatment planning; virus genome; virus hepatitis; virus load; virus replication; virus virulence
Publisher
Oxford University Press
Type
journal article